Interventional Oncology Devices

Global Interventional Oncology Devices Market to Reach US$3.9 Billion by 2030

The global market for Interventional Oncology Devices estimated at US$2.6 Billion in the year 2023, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2023-2030. Embolization Devices, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Ablation Devices segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$675.9 Million While China is Forecast to Grow at 9.5% CAGR

The Interventional Oncology Devices market in the U.S. is estimated at US$675.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$915.6 Million by the year 2030 trailing a CAGR of 9.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Interventional Oncology Devices Market - Key Trends and Drivers Summarized

How Are Interventional Oncology Devices Advancing Cancer Treatment?

Interventional oncology devices are revolutionizing cancer treatment by offering minimally invasive procedures that target tumors with precision, reducing the need for traditional surgery and minimizing damage to surrounding tissues. These devices are used in image-guided procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), and transarterial chemoembolization (TACE), which deliver targeted therapies directly to tumors. Interventional oncology treatments are increasingly being adopted for liver, lung, kidney, and bone cancers, providing patients with safer, less invasive alternatives to open surgery. These technologies are improving survival rates, reducing recovery times, and offering new hope to patients who may not be candidates for traditional surgery.

What Technological Innovations Are Driving Interventional Oncology?

Technological advancements in imaging modalities, robotics, and ablation techniques are driving the growth of interventional oncology. Innovations in imaging technologies, such as MRI, CT, and ultrasound, are enabling real-time, high-resolution visualization of tumors during procedures, improving the accuracy and safety of treatments. Robotic systems are enhancing the precision of interventions, allowing for better targeting of tumors in hard-to-reach areas. New ablation techniques, including microwave ablation and cryoablation, are providing more effective options for tumor destruction while minimizing damage to healthy tissues. These advancements are expanding the capabilities of interventional oncology and allowing for the treatment of a broader range of cancers.

How Do Market Segments Define the Growth of Interventional Oncology Devices?

Device types include ablation devices, embolization devices, and support devices, with ablation devices leading the market due to their widespread use in minimally invasive tumor destruction. Procedures include radiofrequency ablation, microwave ablation, and transarterial chemoembolization, with microwave ablation gaining popularity due to its higher efficacy in treating larger tumors. Cancer types treated with interventional oncology devices include liver, lung, kidney, and bone cancers, with liver cancer being the largest segment due to the high prevalence of hepatocellular carcinoma. The market is growing significantly in regions such as North America and Europe, driven by the availability of advanced healthcare infrastructure and the increasing adoption of minimally invasive treatments.

What Factors Are Driving the Growth in the Interventional Oncology Devices Market?

The growth in the interventional oncology devices market is driven by several factors, including the increasing incidence of cancer, the growing preference for minimally invasive treatments, and advancements in imaging and ablation technologies. As cancer rates rise globally, demand for less invasive and more targeted treatment options is increasing. Interventional oncology offers a solution by providing procedures that are less traumatic for patients and offer faster recovery times. Technological innovations in real-time imaging and precision ablation are further driving market growth by improving the effectiveness and safety of these treatments. Additionally, the rising adoption of interventional oncology in emerging markets, driven by improving healthcare infrastructure and access to advanced medical technologies, is contributing to the expansion of the market.

Select Competitors (Total 36 Featured) -

• AngioDynamics, Inc.
• Boston Scientific Corporation
• BTG plc
• C. R. Bard, Inc.
• Cook Medical LLC
• EDAP TMS S.A.
• Healthtronics, Inc.
• IMBiotechnologies Ltd.
• Medtronic plc
• Merit Medical Systems, Inc.
• Neuwave Medical, Inc.
• Profound Medical Corp.
• Sirtex Medical Limited
• Teleflex Incorporated
• Terumo Corporation
• Trod Medical

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.